Related Experiment Video

Updated: Jun 4, 2025

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.0K

MCP-enhanced SOD3 activity inhibits gastric cancer and potentiate chemotherapy via modulating EGFR signaling

Chao Sun1, Qiushuang Ma1, Liya Feng1

  • 1Department of Pharmacology, Key Laboratory of Chemical Biology, Ministry of Education, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, PR China.

Life Sciences
|January 2, 2025
PubMed
Abstract

Insights

Superoxide dismutase 3 (SOD3) suppresses gastric cancer. Modified citrus pectin (MCP) boosts SOD3, enhancing chemotherapy efficacy and reducing neurotoxicity, offering a novel treatment strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Gastric cancer (GC) remains a significant health challenge.
  • Chemotherapy efficacy is often limited by toxicity, particularly chemotherapy-induced peripheral neurotoxicity (CIPN).
  • The role of superoxide dismutase 3 (SOD3) in GC progression and its therapeutic modulation are not fully understood.

Purpose of the Study:

  • To investigate the tumor-suppressive role of SOD3 in gastric cancer.
  • To evaluate the impact of SOD3 on chemotherapy efficacy and toxicity.
  • To assess the therapeutic potential of modified citrus pectin (MCP) in enhancing SOD3 activity for improved GC treatment and reduced CIPN.

Main Methods:

  • Modulation of SOD3 and Desmocollin2 (DSC2) expression using overexpression plasmids and siRNAs in GC cells.
  • Analysis of pathway-related protein expression and molecular interactions.
  • In vitro and in vivo evaluation of MCP and oxaliplatin (OXA) effects on GC progression and CIPN.

Main Results:

  • SOD3 inhibited GC cell proliferation, migration, and invasion via the SOD3/EGFR/PKP3/DSC2 axis.
  • MCP selectively increased SOD3 levels, enhancing its anti-tumor effects.
  • Combined MCP and OXA synergistically inhibited GC progression, while MCP alleviated CIPN, allowing for OXA dose reduction without compromising efficacy.

Conclusions:

  • SOD3 acts as a tumor suppressor in gastric cancer by regulating the SOD3/EGFR/PKP3/DSC2 axis.
  • MCP enhances chemotherapy efficacy and reduces peripheral neurotoxicity by selectively boosting SOD3 levels.
  • This study presents a promising strategy for improving gastric cancer treatment and mitigating chemotherapy-related side effects.
Keywords:
Chemotherapy-induced peripheral neuropathyGastric cancerModified citrus pectinOxaliplatinSOD3

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.6K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
147
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K